TEAD3 and cancer: Our findings align with emerging efforts to target immunosuppressive metabolic pathways in cancer [42, 43], and importantly, identify TEAD3 not only as a mediator of aggressiveness but also as a potential biomarker for stratifying patients who may benefit from combined metabolic-immune targeting.